Robert John Amato
Impact in
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers
-
- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
Papers in
-
- Renal cell carcinoma treatment 38
- Prostate Cancer Treatment and Research 16
- Oncology 34
- Cancer Immunotherapy and Biomarkers 9
- Co-authors
- Christopher J. Logothetis (29 shared papers)Avishay Sella (11 shared papers)Jaroslaw Jac (8 shared papers)Lorenzo G. Cohen (5 shared papers)Carl de Moor (5 shared papers)Jae Yoon Ro (10 shared papers)Pramod Kumar Srivastava (1 shared paper)Somyata Saxena (8 shared papers)
- Journals
- The Journal of Urology (16 papers)Cancer (11 papers)Urologic Oncology Seminars and Original Investigations (9 papers)Clinical Genitourinary Cancer (9 papers)Urology (8 papers)
- Partner nations
- United StatesUnited KingdomJapan
In The Last Decade
Robert John Amato
160 papers receiving 6.6k citations
Robert John Amato's Hit Papers
Peers
Comparison fields: 5 of 135
- Oncology 2.1k
- Pulmonary and Respiratory Medicine 2.2k
- Cancer Research 770
- Immunology 1.0k
- Surgery 1.6k
Countries citing papers authored by Robert John Amato
This map shows the geographic impact of Robert John Amato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert John Amato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert John Amato more than expected).
Fields of papers citing papers by Robert John Amato
This network shows the impact of papers produced by Robert John Amato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert John Amato. The network helps show where Robert John Amato may publish in the future.
Co-authors
The 25 scholars most cited alongside Robert John Amato, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 164 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2021 | 488 |
| 2 | 2008 | 411 | |
| 3 | 2001 | 317 | |
| 4 | 2005 | 194 | |
| 5 | 2010 | 187 | |
| 6 | 2000 | 183 | |
| 7 | 2009 | 169 | |
| 8 | 2010 | 157 | |
| 9 | 1992 | 136 | |
| 10 | 2001 | 134 | |
| 11 | 2008 | 132 | |
| 12 | 2008 | 130 | |
| 13 | 2003 | 123 | |
| 14 | 2002 | 121 | |
| 15 | 2005 | 108 | |
| 16 | 2004 | 108 | |
| 17 | 2003 | 107 | |
| 18 | 2002 | 100 | |
| 19 | 2009 | 99 | |
| 20 | 2011 | 99 |
About Robert John Amato
Robert John Amato is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Surgery, Immunology and Cancer Research, having authored 164 papers that have together received 6.9k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (38 papers), Testicular diseases and treatments (24 papers), Renal and related cancers (18 papers), Prostate Cancer Treatment and Research (16 papers), Immunotherapy and Immune Responses (14 papers), Cancer Genomics and Diagnostics (12 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Virus-based gene therapy research (9 papers). The work is most often cited by research in Oncology (2.1k citations), Pulmonary and Respiratory Medicine (2.2k citations), Cancer Research (770 citations), Immunology (1.0k citations) and Surgery (1.6k citations). Robert John Amato has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include Christopher J. Logothetis, Avishay Sella, Jaroslaw Jac, Lorenzo G. Cohen, Carl de Moor, Jae Yoon Ro, Pramod Kumar Srivastava, Somyata Saxena, Julie A. Ellerhorst and Bin Sing Teh. Their work appears in journals such as The Journal of Urology, Cancer, Urologic Oncology Seminars and Original Investigations, Clinical Genitourinary Cancer and Urology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.